Lantern Pharma Inc.
NASDAQ:LTRN
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
2.94
10.65
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Lantern Pharma Inc.
Revenue
Lantern Pharma Inc.
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Lantern Pharma Inc.
NASDAQ:LTRN
|
Revenue
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Abbvie Inc
NYSE:ABBV
|
Revenue
$55.5B
|
CAGR 3-Years
0%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
||
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$28.3B
|
CAGR 3-Years
1%
|
CAGR 5-Years
5%
|
CAGR 10-Years
3%
|
||
Amgen Inc
NASDAQ:AMGN
|
Revenue
$32.5B
|
CAGR 3-Years
8%
|
CAGR 5-Years
7%
|
CAGR 10-Years
5%
|
||
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$10.6B
|
CAGR 3-Years
14%
|
CAGR 5-Years
24%
|
CAGR 10-Years
30%
|
||
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.8B
|
CAGR 3-Years
1%
|
CAGR 5-Years
16%
|
CAGR 10-Years
18%
|
Lantern Pharma Inc.
Glance View
Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. The company is headquartered in Dallas, Texas and currently employs 14 full-time employees. The company went IPO on 2020-06-11. The firm is focused on leveraging artificial intelligence (AI), machine learning and genomic data to streamline the drug development process and to identify the patients, which benefits from its targeted oncology therapies. The Company’s therapies portfolio consists of small molecule drug candidates and new compounds, which it is developing with the assistance of its AI platform and its biomarker driven approach. The Company’s AI platform, RADR uses big data analytics, including combining molecular data, drug efficacy data, data from historical studies, data from scientific literature, phenotypic data from trials and publications, and mechanistic pathway data, and machine learning. The Company’s data-driven, gnomically targeted and biomarker-driven approach allows it to pursue a transformational drug development strategy, which identifies, rescues or develops, and advances potential small molecule drug candidates.
See Also
What is Lantern Pharma Inc.'s Revenue?
Revenue
0
USD
Based on the financial report for Dec 31, 2023, Lantern Pharma Inc.'s Revenue amounts to 0 USD.